Jonsson Comprehensive Cancer Center
🇺🇸United States
Vaccine Therapy in Treating Patients With Malignant Glioma
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Biological: glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00612001
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Temozolomide in Treating Patients With Invasive Pituitary Tumors
Phase 2
Withdrawn
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00601289
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Lung Cancer
- Interventions
- Biological: autologous dendritic cell-adenovirus CCL21 vaccine
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00601094
- Locations
- 🇺🇸
VA Greater Los Angeles, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Patient-Directed Lifestyle Change and Health Promotion Program or Usual Care in Low-Income, Uninsured Participants in Los Angeles County, California
Not Applicable
Completed
- Conditions
- Impoverished Population
- Interventions
- Other: Stand procedures, no interventionBehavioral: Self-Care Stimulating Disease Prevention Program (SCSDPP)
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 97
- Registration Number
- NCT00521209
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00509431
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
Phase 2
Completed
- Conditions
- Melanoma (Skin)
- Interventions
- Biological: CP-675,206
- First Posted Date
- 2007-05-10
- Last Posted Date
- 2020-10-26
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00471887
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer
Withdrawn
- Conditions
- DepressionFatigueOvarian CancerPsychosocial Effects of Cancer and Its TreatmentSleep Disorders
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00460200
Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00450567
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants
Not Applicable
Terminated
- Conditions
- Lung Cancer
- Interventions
- Procedure: fluorine F 18 FEQA + positron emission tomography
- First Posted Date
- 2007-03-07
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00444223
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
Not Applicable
Completed
- Conditions
- Breast CancerUnspecified Adult Solid Tumor, Protocol SpecificSarcomaLung CancerOvarian CancerProstate Cancer
- Interventions
- Biological: trastuzumab
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00433407
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath